Late payments from Dutch partners can pose significant challenges for US pharma firms. These challenges include the impact on cash flow, difficulty in meeting financial obligations, and strained relationships with Dutch partners. In order to address these challenges, US pharma firms can implement various strategies such as establishing clear payment…